Cytokinetics to Hold Annual Meeting of Stockholders

Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [4] - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from the SEQUOIA-HCM Phase 3 clinical trial [4] - Other products in development include omecamtiv mecarbil for heart failure with severely reduced ejection fraction (HFrEF), CK-586 for heart failure with preserved ejection fraction (HFpEF), and CK-089 for specific muscular dystrophies [4] Annual Meeting Details - Cytokinetics will hold its Annual Meeting of Stockholders on May 14, 2025, at 10:00 AM Pacific Time at its headquarters in South San Francisco [1] - Stockholders of record as of March 24, 2025, are entitled to vote or attend the meeting in person [2] - A live webcast of the meeting and subsequent company update presentation will be available, with an archived replay accessible for twelve months [3]